A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Required: CD19 positive expression (positive)

Required: CD20 positive expression (positive)

Must have received: anti-CD20 antibody

after ≥ two lines of systemic therapy, including anti-CD20 antibody and anthracycline

Must have received: anthracycline

after ≥ two lines of systemic therapy, including anti-CD20 antibody and anthracycline

Cannot have received: CAR T cell product

Previously treated with any CAR T cell product

Cannot have received: allogenic hematopoietic stem cell transplant

Previously treated with ... allogenic hematopoietic stem cell transplant (HSCT)

Cannot have received: investigational product, cell therapy, or gene therapy

Received any other investigational product, cell therapy, or gene therapy within 12 weeks prior to the leukapheresis

Cannot have received: tyrosine kinase inhibitor

Received any tyrosine kinase inhibitor within 2 weeks prior to the leukapheresis

Cannot have received: systemic steroid

Received any systemic steroid ... within 4 weeks prior to the leukapheresis

Cannot have received: immunotherapy (immune checkpoint inhibitors, T-cell transfer therapies, monoclonal antibodies)

Received any ... immunotherapy (such as immune checkpoint inhibitors, T-cell transfer therapies, monoclonal antibodies) ... within 4 weeks prior to the leukapheresis

Cannot have received: chemotherapy

Received any ... chemotherapy within 4 weeks prior to the leukapheresis

Cannot have received: live vaccine

Received any live vaccine from 2 weeks prior to the leukapheresis